Related Experiment Video
Updated: Feb 3, 2026

Author Spotlight: Understanding Disease Mechanisms Through Real-Time Analysis of T-Cell Migration
Published on: May 24, 2024
Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro
Agnieszka Jasiecka-Mikołajczyk1, Jerzy J Jaroszewski1, Tomasz Maślanka1
1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowski Street 13, 10-719 Olsztyn, Poland.
Abstract:
Oclacitinib (OCL) is a novel immunosuppressive agent approved for dogs that controls itch and inflammation in allergic disease via the inhibition of the JAK/STAT pathway. This paper investigates the in vitro effect of OCL, a novel Janus kinase inhibitor, on selected canine regulatory (Treg) and effector (Teff) CD4+ and CD8+ T cells. Exposure of peripheral blood lymphocytes to OCL did not affect the transcription factor Foxp3 (Forkhead Box P3 protein) expression in CD25+CD4+ and CD25+CD8+ T cells. Moreover, OCL did not influence constitutive CD25 expression on these cells although it reduced the activation-induced CD25 expression on CD4+ T cells. Unexpectedly, the research demonstrated the cytoreductive and proapoptotic effects of OCL on the cells examined. Exposure to OCL caused a dramatic loss of both CD4+ and CD8+ T cells and this effect was observed in both Treg and Teff cell subsets. On the one hand, cytoreductive and proapoptotic effects of OCL toward CD4+ and CD8+ Teff cells, as well as the drug-induced inhibition of CD4+ T cell activation, may be considered as additional mechanisms involved in producing anti-inflammatory and anti-allergic properties of the drug. On the other hand, these effects also represent the immunosuppressive action in the sense of an unwanted effect because CD4+ and CD8+ Teff cells play a crucial role in the production of cellular immunity. Further studies are needed to determine whether the use of OCL actually creates the risk of such action.
Insights
Oclacitinib (OCL), a JAK inhibitor, unexpectedly reduced canine T cells (CD4+ and CD8+), including regulatory and effector subsets. While potentially contributing to anti-inflammatory effects, this immunosuppression warrants further investigation for safety concerns.
Area of Science:
- Immunology
- Veterinary Pharmacology
- Cell Biology
Background:
- Oclacitinib (OCL) is an immunosuppressive drug used in dogs to manage allergic skin disease by inhibiting the JAK/STAT pathway.
- Understanding OCL's precise effects on canine T cell subsets is crucial for evaluating its therapeutic efficacy and potential side effects.
Purpose of the Study:
- To investigate the in vitro effects of OCL on canine regulatory T cells (Tregs) and effector T cells (Teffs), specifically CD4+ and CD8+ T cell subsets.
- To assess OCL's impact on T cell activation markers and its potential cytoreductive and proapoptotic effects.
Main Methods:
- Peripheral blood lymphocytes from dogs were exposed to OCL in vitro.
- Flow cytometry was used to analyze the expression of Foxp3 and CD25 on CD4+ and CD8+ T cells.
- Cytoreductive and proapoptotic effects of OCL on T cell populations were evaluated.
Main Results:
- OCL did not alter Foxp3 expression in CD25+CD4+ and CD25+CD8+ T cells.
- OCL did not affect constitutive CD25 expression but reduced activation-induced CD25 expression on CD4+ T cells.
- Unexpectedly, OCL exhibited significant cytoreductive and proapoptotic effects, leading to a dramatic loss of both CD4+ and CD8+ T cells across Treg and Teff subsets.
Conclusions:
- OCL's reduction of T cell activation and its cytoreductive/proapoptotic effects on T cells may contribute to its anti-inflammatory and anti-allergic properties.
- These observed immunosuppressive effects, however, raise concerns about potential adverse outcomes due to the critical role of T cells in cellular immunity.
- Further research is necessary to determine the clinical implications and risks associated with OCL-induced T cell depletion in dogs.
More Related Videos
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
08:20In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol
Published on: December 30, 2016
Related Concept Videos
MOSFET: Depletion Mode
The primary characteristic of depletion-mode MOSFETs is their ability to conduct current between the drain and source terminals without gate bias. This inherent conductivity...
In-vitro Mutagenesis
In Vitro Fertilization
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
Batteries and Fuel Cells
Equivalence: In Vitro and In Vivo Bioequivalence
In Vitro Drug Dissolution: Alternative Methods